Celgene and Pfizer returned for small molecule drug developer Arrakis Therapeutics' latest round, which included GV and Wuxi AppTec Fund.

US-based biopharmaceutical company Arrakis Therapeutics has closed a $75m series B round that included internet technology group Alphabet and pharmaceutical firms WuXi AppTec, Celgene and Pfizer.

VenBio Partners and Nextech Invest co-led the round, which also featured Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities.

Osage University Partners (OUP), Omega Funds, HBM Healthcare Investments, Canaan Partners, Advent Life Sciences and private investor Henri Termeer filled out the round. Alphabet, WuXi…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn